Hema Now
In this episode of Hema Now, Lucas Kühne explores the evolving landscape of immune thrombotic thrombocytopenic purpura, discussing advances in treatment, the importance of early recognition and accurate diagnosis, the growing role of real-world evidence, and why international collaboration is critical to accelerating research and improving patient care in rare thrombotic microangiopathies.
Spotify | Apple | Amazon Music | YouTube | Download MP3
Lucas Kühne is a specialist in Internal Medicine and researcher at University Hospital Cologne, Germany. After completing his medical training at the Universities of Cologne and Freiburg, with clinical electives in Southampton, UK, and Luxembourg, he developed a particular interest in thrombotic microangiopathies, especially immune thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome.
Timestamps:
00:00 – Introduction
01:40 – Career inspiration and TMA interest
03:11 – Major advances in iTTP treatment
05:05 – Recognising iTTP earlier
07:08 – Distinguishing between TMAs
09:05 – Value of real-world evidence
12:13 – Future priorities in iTTP research
13:32 – Importance of research collaboration
14:57 – Advice for future researchers
15:53 – Future of TMA care
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Keywords: immune thrombotic thrombocytopenic purpura, thrombotic microangiopathy, rare blood disorders
